Muscle Mitochondrial Function in Patients with Type 2 Diabetes Mellitus and Peripheral Arterial Disease: Implications in Vascular Surgery  by Pedersen, B.L. et al.
Eur J Vasc Endovasc Surg (2009) 38, 356e364REVIEW
Muscle Mitochondrial Function in Patients with Type
2 Diabetes Mellitus and Peripheral Arterial Disease:
Implications in Vascular SurgeryB.L. Pedersen a,*, N. Bækgaard a, B. Quistorff ba Department of Vascular Surgery, Gentofte Hospital, Niels Andersens Vej 65, 2900 Hellerup, Denmark
b Nuclear Magnetic Resonance Centre, Department of Biomedical Sciences, The Panum Institute, University of Copenhagen,
Denmark
Submitted 20 April 2009; accepted 20 April 2009
Available online 12 June 2009KEYWORDS
Muscle energy metabo-
lism;
Mitochondrial function;
Peripheral bypass
surgery;
Diabetes type 2;
Clinical outcome* Corresponding author. Tel.: þ45 6
E-mail addresses: brlipe01@geh.re
pedersen@hotmail.com (B.L. Pederse
1078-5884/$36 ª 2009 European Socie
doi:10.1016/j.ejvs.2009.04.014Abstract Objectives: (1) To review the available information on mitochondrial function in
type 2 diabetes mellitus (T2DM) and peripheral arterial disease (PAD) obtained by non-invasive
phosphor magnetic resonance spectroscopy (31PMRS), near-infrared spectroscopy (NIRS) in vivo
and respirometry on mitochondria isolated from muscle biopsies in vitro (2) to evaluate the
usefulness of such data in the diagnosis, treatment and prognosis of these patients.
Design: Review.
Methods: Search strategy: PubMed (http://www.ncbi.nlm.nih.gov/PubMed) and manual liter-
ature search.
Main results: Fifty-three articles were retrieved, which included 31PMRS, 15, NIRS, 11,
Combined, 1 and Respirometry, 2 and background literature, 24.
Conclusion: Muscle mitochondrial function is impaired in both T2DM and PAD patients, but
differently. Patients suffering from both pathological conditions will display more serious
impairment of the mitochondrial function. Mitochondrial function and the degree of ischaemic
disease as evaluated by 31PMRS and NIRS are well correlated. The NIRS technique appears to
determine the degree of PAD better than 31PMRS. It is argued that systematic testing of mito-
chondrial function may be a useful prognostic tool with PAD and T2DM, but clinical studies are
needed.
ª 2009 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.1275901.
gionh.dk, brian_lindegaard_
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ty for Vascular Surgery. PublisheThe muscle mitochondria serve as the energy-generating
organelle in the majority of cells of the body, including
muscle cells. Patients affected by T2DM (type 2 diabetes
mellitus) and PAD (peripheral arterial disease) have somed by Elsevier Ltd. All rights reserved.
Muscle Mitochondrial Function in Patients 357degree of mitochondrial dysfunction, which may have
serious consequences for the muscle function and the
mobility of these patients. Mitochondrial function in
cellular energy metabolism is concerned with the processes
of fatty acid and pyruvate oxidation, resulting in the
formation of acetyl-CoA, which is subsequently oxidised in
the TCA cycle. When combined, these processes generate
reduced coenzymes, which, through the respiratory chain
of the inner membrane, deliver electrons to oxygen to form
water. The whole process of fat and carbohydrate oxidation
is strongly exergonic and the normal mitochondrion
conserves the major part of this energy in the form of ADP
phosphorylation to ATP. This dependence on oxygen is
critical in skeletal muscle, which, under normal circum-
stances, has the capacity to increase its energy turnover by
some 50-fold, making the transition from rest to maximal
exercise.1 Efficient oxygen delivery, therefore, becomes of
paramount importance for normal mitochondrial function.
Thus, in all diseases involving the circulatory system,
either the pumping function and/or the vascular bed,
symptoms of abnormal mitochondrial function will even-
tually arise. T2DM and PAD are two such illnesses with
vascular involvement. Patients suffering from PAD have
a decreased blood flow to the legs due to arteriosclerosis,
making less oxygen available to the mitochondrias. Type 2
diabetics have a high occurrence of PAD, but the arterio-
sclerosis is located more distally and differently distributed
in the arterial wall (media sclerosis).
As diagnostic measures, it is logical to choose methods
that evaluate the mitochondrial energy transformation,
either directly as with 31phosphorous magnetic resonance
spectroscopy (31PMRS) or indirectly as with near-infrared
spectroscopy (NIRS), due to its ability to monitor the tissue
oxygen level. Both techniques are non-invasive and, in
particular, the NIRS technique is unique by its simplicity and
portability. In addition, mitochondrial function may be
evaluated in vitro by respirometry on relatively small
(30e50 mg) muscle biopsies.
31PMRS
The 31PMRS is a non-invasive method used for determination
of relative concentrations of metabolites involved in muscle
energy metabolism in vivo (i.e., PCr (phosphocreatin), Pi
(inorganic phosphate) and ATP (adenosine triphosphate)).2
From these data, free ADP (adenosine diphosphate) and pH
may be calculated as well as the anaerobic and aerobic ATP
turnover.3,4 The 31PMRS is a dynamic method with a time
resolution of down to 5e10 s, which can be used at rest and
during exercise by placing the patient in the magnet and the
magnetic resonance (MR) probe on the relevant muscle.5e19
The re-synthesis of PCr, which is deprived during exercise
and ischaemia, is an indirect measure of aerobic mito-
chondrial function (i.e., rate of maximal ATP synthesis).3
NIRS
The NIRS can measure the state of oxygen saturation in
haemoglobin and myoglobin in blood and muscle at a given
time and a given location, thereby providing an indirect
measure of the muscle perfusion vs. oxygen consumption.The method works by placing the NIRS probe on the skin
overlying the relevant muscle, on which oxygenation is
estimated. Light at specific wavelengths in the near-
infrared spectral region may penetrate the muscle tissue
and the absorption at specific wavelengths (typically 760,
800 and 900 nm) allows the calculation of the tissue
oxygenation (0e100%).20e31
Respirometry
Respirometry is an in vitro technique that quantifies mito-
chondrial oxygen consumption under specific circumstances
with regard to substrate supply, with and without specific
inhibitors.32e35 The method is invasive since it requires the
sampling of a muscle biopsy (50e100 mg (wet weight) of
tissue).32,34 The sarcolemma of the muscle fibres is
removed with saponin revealing the mitochondrias in the
cytoplasma of the muscle cell. The biopsy is examined in
chambers with oxygen electrodes for measuring the oxygen
consumption with different substrates added.32e35
Methods
Article search limits
Inclusion criteria: Articles addressing NIRS, 31PMRS and
respirometry in combination with either PAD, T2DM,
peripheral bypass surgery or all of them were included.
Literature was found using the search function in PubMed
(http://www.ncbi.nlm.nih.gov/PubMed) and by manual
search. The search was conducted using words such as NIRS,
Respirometry, ischaemic muscle, magnetic resonance
spectroscopy, diabetes (type 2), claudication, mitochon-
drial function, graft patency and peripheral bypass surgery.
Exclusion criteria: Case reports and articles describing
aortic aneurism surgery were excluded.
Additional literature was found in the above process.Results
Mitochondrial function expressed as oxidative recovery
after exercise is related to the degree of disease of both
T2DM and PAD.12,22,23 The results are therefore presented
according to the degree of ischaemic disease (as defined by
the TASC II consensus report36) and with and without T2DM.
Patients with functional ischaemia
At rest, muscle metabolism and tissue viability are only
slightly affected in this group of patients as determined by
31PMRS (245 patients in 12 studies (range: 7e56patients)) and
theNIRS (481 patients in 11 studies (range: 6e153)). 5e16,20e31
During exercise, however, 31PMRS shows an increased
PCr splitting, correspondingly higher Pi (increased Pi/PCr
ratio) and eventually a drop of pH by the end of exercise,
indicating that anaerobic metabolism has commenced.
Furthermore, an increased recovery time of the PCr, ADP
concentrations and pH is seen. This applies to patients with
both moderate and critical ischaemia independent of the
358 B.L. Pedersen et al.choice of training protocol (isotonic or isometric) (245
patients, p< 0.001e0.05).5e16
The NIRS measurements in the gastrocnemius muscle
during exercise show a large drop in the oxygen saturation
in the muscle and an increased oxygenation recovery time
after exercise when compared to age-matched con-
trols10,20e25,28,29 (339 patients, p< 0.009e0.045). The
observed drop in oxygen saturation is abnormal, even when
compared to normal controls with tourniquet-restricted
blood flow.22 An increased drop in the oxygen saturation at
the beginning of exercise has been observed by Bauer
et al.20 This suggests a decreased blood supply in patients
with PAD due to their impaired blood-flow response during
exercise. On the other hand, histological and EM examina-
tions have paradoxically identified more type I muscle
fibres containing a high amount of mitochondria in the
gastrocnemius muscle of claudication patients compared to
controls. Furthermore, an increased percentage of type I
fibres was correlated with the severity of PAD.37
Chronic critical limb ischaemia
In patients at rest, 31PMRS examination showed a higher Pi/
PCr ratio and higher intracellular pH compared to controls
(45 patients, p< 0.005e0.02).17e19 Similar examinations
with NIRS have been conducted by Eiberg et al. during and
after bypass surgery.30,31 These measurements indicated
decreased oxygen saturation during surgery, with return to
supernormal levels as expected after completion of the
operation. Like most other NIRS measurements, only
oxygenation changes are reported, and there is no infor-
mation about actual oxygen consumption.
Only two studies have been performed that applied
respirometry on permeabilised human muscle fibres in this
patient group. Both the studies found a reduced mito-
chondrial respiratory rate (nano-atoms of oxygen per
minute; 34 patients (35 legs)) in the gastrocnemius muscle
compared to controls.32,33
In one of the studies, the reduced respiratory rate was
located specifically to enzyme complexes I, III and IV of the
respiratory chain. In this study as well, a dysfunctional
capacity of anti-oxidative enzymes in both mitochondria
and cytosol in PAD muscles was found, implying that the
decreased activity of complexes I, II and IV may be due to
reactive oxygen species (ROS)-generated damage.32
Consequently, PAD patients may not gain from the
increased amount of mitochondrias as they are
dysfunctional.T2DM and PAD
Patients suffering from both PAD and T2DM are associated
with higher mortality than PAD alone (47% vs. 36%, 6-year
observational period), and the prospects after re-vascu-
larisation are low38 despite the presence of similar graft
patency rates after bypass surgery.39 Prolonged healing of
ischaemic tissue lesions after bypass surgery is also seen
within this group.40
Patients with T2DM have a well-documented impaired
ability to exercise. Muscle weakness is often experienced,
characterised by reduced strength and endurance.41Patients with PAD and T2DM have a reduced ability to
exercise when compared to patients with PAD alone in spite
of similar ankle-brachial indices (ABIs).42 The reason for
this phenomenon is related to the pathology and compli-
cations of T2DM. The insulin resistance may impair muscle
metabolism by reducing the substrate supply. The lipid
accumulation seen in the muscle cell has been shown to
cause muscle weakness in T2DM.41 A group of particular
high risk is type 2 diabetics with neuropathy, which have
serious consequences for both muscle function and devel-
opment of foot ulcers.43
Type 2 diabetics have a decreased amount of type I
muscle fibres, which contain a larger amount of mito-
chondrias when compared to type II muscle fibres.44 Rabøl
et al.45 confirmed this by a reduced mitochondrial content
in muscle biopsies from type 2 diabetics.
31PMRS measurements of the capacity for aerobic ATP
formation in the same patient group correlate with this
finding.46 Muscle fibre transition is also seen in other
muscles in both human and animal models. Atrophy of type
I muscle fibres is seen together with an increased amount of
type II fibres, which are decreased in size. The remaining
type I fibres are increased in size and mitochondrial
content. Both diabetes and neuropathy can cause this fibre-
type transistion.41,47 The altered fibre-type composition
could explain the impaired endurance and strength.48 This,
however, is not the whole explanation since T2DM is asso-
ciated with co-morbidity of a complex pathology.49
In a small patient serie, an increased accumulation of
phosphate monoesters is seen after exercise in patients
with chronic ischaemia and diabetes using 31PMRS
measurements when compared to patients with chronic
ischaemia and no diabetes.16 No other 31PMRS study has
addressed patients with chronic ischaemia and diabetes.
The NIRS measurements in the gastrocnemius muscle in
patients with diabetes and PAD have shown a better
determination of the degree of ischaemia when compared
to measurement of the ABI.23 Furthermore, a decreased
micro-vascular response during exercise has been shown in
the legs of diabetics. The micro-vascular blood flow
in patients with PAD increases to supernormal levels,
probably in order to compensate for the lack of blood flow
from the greater arterial vessels. In this sense, diabetics
are not able to use this compensatory mechanism where
even the normal response to exercise is impaired.26
The muscle fibre transitions for patients with combined
PAD and T2DM are not yet characterised.
The articles are summarised in Table 1.
Peripheral bypass surgery, angioplasty, graft
patency and mitochondrial function
31PMRS has been used in two studies tomeasure the effect on
muscle metabolism of peripheral bypass surgery and angio-
plasty. The study done by Schunk et al.13 examines 31
patients before and after vascular therapy; of which 23
patients were treated with percutaneous transluminal
angioplasty and eight with vascular surgery (four bypass and
four thrombectomies). The severity of their symptoms was
classified according to the modified Fontaine classifica-
tion.13 The majority of the patients were claudicants with
different walking distances (modified Fontaine stage IIaec).
Table 1 Summation of the biochemical and physiological changes of PAD and T2DM in the reviewed articles
Functional
ischaemia
Reference Critical ischaemia Reference PAD and
diabetes type 2
Reference
31PMRS At rest: no effect
on muscle metabolism.
During exercise:
Increased PCr
degradation, higher
Pi concentration
(Increased Pi/PCr
ratio) and a lower
end exercise pH.
Increased recovery
time for PCr, ADP and
end exercise pH.
Improvement in 31
PMRS parameters
(intracellular pH, Pi/PCr
ratio, PCr recovery)
during exercise after
peripheral bypass
surgery.
Di marzo et al.5;
Greiner et al.6;
Hands et al.7;
Keller et al.8;
Kemp et al.9,10;
Pipinos et al.11;
Schunk et al.12,13;
Tsuchiba et al.27;
Von Melchert et al.14;
Wahl et al.15
At rest: higher Pi/
PCr ratio and higher
intracellular pH.
During exercise:
Increased PCr
degradation, higher
Pi concentration
(Increased Pi/PCr
ratio) and a lower
end exercise pH.
Increased recovery
time for PCr, ADP
and end exercise pH.
Delayed improvement
in 31PMRS parameters
(intracellular pH, Pi/
PCr ratio, PCr recovery)
during exercise after
peripheral bypass
surgery.
Hands et al.17,18;
Zatina et al.19
Correlation of muscular
oxidative capacity to a
decreased amount of
type I muscle fibres in
diabetics.
Increased accumulation of
phosphate monoesters is seen
after exercise in patients with
chronic ischaemia and
diabetes compared to patients
with chronic ischaemia and
no diabetes.
Praet et al.46;
Zatina et al.19
NIRS At rest: no effect on
muscle metabolism
During exercise: A
large drop in the
oxygen saturation in
the muscle and an
increased recovery
time after exercise.
Increased drop in
oxygen saturation
at the beginning of
exercise.
Bauer et al.20;
Comerota et al.21;
Egun et al.22;
Kemp et al.10;
Komiyama et al.23;
Kooijman et al.24;
McCully et al.25;
Watanabe et al.29;
Ubbink and Koopman28
Decreased oxygen
consumption at rest.
Improved muscle
oxygenation after
peripheral bypass
surgery.
Eiberg et al.30,31 Better determination of the
degree of ischaemia when
compared to measurement
of the ABI.
Decreased micro vascular-
response during exercise in
the legs of diabetics.
Komiyama et al.23;
Mohler et al.26
Respirometry Muscle mitochondrial
dysfunction has been
found as a reduced
oxidative capacity
Pipinos et al.32,33;
Rabøl et al.45
Reduced amount of
mitochondrias in patients
with type 2 diabetes and
hereby reduced oxidative
capacity
Rabøl et al.45
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360 B.L. Pedersen et al.Only two patients had resting pain before treatment. After
surgery, an improvement in symptoms and haemodynamic
parameters (ABI) was seen in all patients studied, this was
also reflected in an improvement in the 31PMRS parameters
(intracellular pH, Pi/PCr ratio, PCr recovery) during the
conducted exercise protocol (isometric and isotonic) in the
rectus femoral muscle indicating reversibility of the mito-
chondrial dysfunction. The post-treatment 31PMRS
measurements were obtained 25 6 days after treatment.
Zatina et al.19 obtained different results although not
significant. The post-treatment results in this study indi-
cated a prolonged recovery of the 31PMRS parameters of up
to several months after treatment even though the hae-
modynamic parameters had recovered. These results indi-
cate impaired oxygen consumption, which is not due to
post-treatment ischaemia.
The patients and their corresponding clinical stage and
type of treatment are not described in the article for the
data obtained after treatment, which complicates
the interpretation. The 31PMRS data were obtained in the
gastrocnemius muscle, which is situated more distal than
the rectus femoral muscle studied by Schunk et al., which
may have serious consequences for the muscle metabolism
parameters in patients with PAD.16
Graft patency studies have never been conducted with
31PMRS measurements and respirometry before. Eiberg
et al. have conducted two NIRS studies,30,31 where graft
patency was considered, one in the foot and the other in
the gastrocnemius muscle in a mixed patient population
according to clinical stage, graft material and type of
bypass operation. Both studies were done in small patient
groups and showed immediate recovery of the haemody-
namic parameters measured with NIRS after completion of
the bypass operation. This correlate well with the studies
of Zatina et al.19 and Schunk et al.,13 where the haemo-
dynamic parameters measured as ABI also recovered fast
after bypass surgery. No haemodynamic flow characteristics
measured with NIRS were able to predict graft patency in
the studies done by Eiberg et al.29,30
Graft patency is shown in several studies to depend on
several factors, including choice of graft material, the type
of surgical technique, ABI< 0.40 and other co-morbidity
risk factors.50,51Discussion
The available data indicate that the mitochondrial function
is well correlated by the degree of PAD. This correlation
has, however, not been shown in patients with T2DM
separately. Is mitochondrial damage/dysfunction a relevant
predictor of functional outcome of re-vascularisation in
patients with T2DM and PAD?
The most important predictors of a poor functional
outcome of bypass surgery in PAD with and without dia-
betes have been identified by Taylor et al.38 to be:
(1) impaired ambulatory ability at the time of presen-
tation, (2) failure to eventually ambulate (walk), (3) loss of
independent living and (4) dementia. This indicates that for
a patient with bad mobility before re-vascularisation the
chance of extensive improvement is low, although it might
have helped in salvaging a leg and healing the wounds. The
PAD 
Decreased mitochondrial function due to
Reduced oxygen supply 
Increased amount of mitochondrias
which are dysfunctional  
Damage of the mitochondrial
 ultrastructure
Higher amount of type I muscle fibers
with high mitochondrial content  
Type 2 diabetes 
Decreased mitochondrial function 
due to Decreased amount of type 
I muscle fibers with
 high mitochondrial content  
Increased amount of type II 
muscle fibers with low
mitochondrial content  
Figure 1 Changes in the mitochondrial amount and function in patients with PAD and T2DM.
Muscle Mitochondrial Function in Patients 361diabetic patients fall in to this group because the patho-
physiology of the disease impairs the muscle function and
thereby the mobility, as explained earlier. Patients with
diabetes have a higher mortality rate, higher frequency of
failed ambulation and loss of independent living.38 This
poor functional result amongst the diabetics is probably
a reflection of several (many accumulated) independent
risk factors such as a higher frequency of cardiac disease
and renal failure. Whatever the reason of the impaired
mobility, the level of oxidative ATP synthesis (mitochon-
drial function) in the muscle will properly correlate with
mobility, as indicated in the studies reviewed above. This
suggests that muscle oxidative metabolism, and thereby
mitochondrial function, could be a predictor of functional
outcome. Obviously, further prospective studies of bothPAD 
claudicants
Diabetes No Diabetes 
NIRS in the
Diagnosis of PAD  
31PMRS to monitor
 effects of different 
treatments in research 
Figure 2 Suggested future use of 31PMRS and NIRS in different pfunctional outcome and muscle metabolism are needed to
build a strong argument for this claim.
The presented literature addressing the muscle tissue
viability in T2DM and PAD describes a theoretical disad-
vantage for diabetics in the fibre-type composition of the
muscles, which is in contrast to patients with PAD only. This
is because an increased amount of type I muscle fibres is
seen, which probably is a compensating mechanism due to
chronic ischaemia. Data are only available for patients with
either T2DM or PAD (Fig. 1). Muscle biopsies of the
combined disease are not currently available.
Surprisingly few studies have been conducted addressing
the combined effect on muscle metabolism of T2DM and
PAD. Measurements with the three methods mentioned
above and after bypass surgery have only been conductedCritical ischemia 
Diabetes No Diabetes
NIRS in the
Diagnoses and
Prediction of
outcome in bypass
surgery
 
 
NIRS in the
prediction of outcome
in bypass surgery   
31PMRS in selected
 Cases to predict
outcome  
31
 PMRS in selected 
Cases to predict
 outcome 
atient groups with PAD.
Bypass surgeryDiagnosis Angiography
time
6-8 weeks follow up 1 year follow up
NIRS 31PMRS NIRS NIRS 
Figure 3 Suggested use of NIRS and 31PMRS in bypass surgery treatment and follow up. Time line showing placement of the
individual tests in a typically patient case.
362 B.L. Pedersen et al.in a very limited amount. There are no studies which
examine the number of patients required for clinical use.
Performing a study of this scale is difficult and perhaps even
ethically questionable if muscle biopsies need to be
included. The 31PMRS and NIRS studies could be used in
large series to obtain graft patency because of their non-
invasive nature, although extensive effort on developing
a standardised protocol should be emphasised.
No study has determined whether it is possible to design
a protocol that will provide data based on 31PMRS or NIRS
measurements, which explicitly define poor functional
outcome of bypass surgery although it is likely to be the
case.
Ekert and Scnackerz52 determined 31PMRS values in
human muscle tissue with acute irreversible ischaemia. In
this study, the optimal time for re-vascularisation was
defined as the time point just prior to the PCr concentra-
tion reaching its minimum. The end point where re-vascu-
larisation no longer is possible is defined as the point in
time where the ATP concentration is no longer detectable.
The situation is different in chronic limb ischaemia
where the muscles of the leg are going through repeating
cycles of ischaemia and reperfusion. In critical ischaemia,
we hope that 31PMRS values could be used in detecting the
time point where the mitochondrial damage has reached an
irreversible level, where no gain in muscle function is
achievable by re-vascularisation. These results could be
related to NIRS measurements, which are more feasible in
a clinical setup. This leaves the open question: Is mito-
chondrial dysfunction reversible? If not, are there some
patients who would benefit functionally from bypass
surgery where others will not?
If mitochondrial function is irreversible at some point,
are there some patients who should be operated earlier?
Shunk et al. showed reversibility of mitochondrial function
in patients with mild PAD symptoms measured with 31PMRS;
therefore, at early stages of PAD, mitochondrial function
show reversibility. The limit where the severity of PAD
progresses to a level where mitochondrial function is irre-
versible is not known presently. However, graft patency
should also be considered.
Is it possible to use a combination of PMRS, NIRS
and respirometry in practical clinical work?
In some grafts, flow may be observed, but without apparent
effect on muscle function. In other words, there will be
a certain number of cases with patent grafts but no gain in
leg function. Therefore, we speculate that by actually
testing the status of oxidative metabolism prior to surgery,the outcome of surgery, including mobility of the patient,
would be more predictable. In the reviewed papers
covering the use of 31PMRS, NIRS and respirometry
methods, no direct evidence of a poor clinical outcome in
patients with impaired mitochondrial function has been
obtained, but long-term follow up studies has not been
conducted. Although evidence of good correlation of the
degree of ischaemia and muscle metabolism parameters
exists,12,22,23 it is likely that impaired muscle metabolism is
a predictor of poor clinical outcome similar to what have
been learned from other studies, where the most severely
affected ischaemic limb measured as an ABI below 0.40 will
be a predictor of poor clinical outcome.51 However, the use
of ABI as a predictor in the diabetic group is problematic as
the prognosis could be unreliable. 53 We therefore suggest
that the use of NIRS in this patient group could be a prom-
ising alternative.
In future studies, respirometry could perhaps be
reserved for small groups of patients to determine more
detailed nature of the mitochondrial dysfunction. Such
results could subsequently be related to 31PMRS and NIRS.
A scheme of such future examination programme is
shown in Figs. 2 and 3.Conclusion
Muscle mitochondrial function is impaired in both T2DM
and PAD, but differently. Patients suffering from both
pathological conditions will display more serious impair-
ment of the mitochondrial function. Mitochondrial func-
tion and the degree of ischaemic disease as evaluated by
31PMRS and NIRS are well correlated. The NIRS technique
appears to determine the degree of PAD better than the
31PMRS. It is argued that systematic testing of mitochon-
drial function may be a useful prognostic tool with PAD and
T2DM, but clinical studies to confirm this suggestion are
needed.Conflict of Interest/Funding
None declared.
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